Annovis Bio, Inc.
General ticker "ANVS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $34.1M (TTM average)
Annovis Bio, Inc. does not follow the US Stock Market performance with the rate: -5.4%.
Estimated limits based on current volatility of 2.8%: low 1.70$, high 1.79$
Factors to consider:
- Earnings expected soon, date: 2026-08-11 bmo
- Total employees count: 6 (+20.0%) as of 2023
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient capital, Clinical trial failure, Regulatory and compliance, Commercialization challenges, Key person loss
- Current price 20.8% below estimated low
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.21$, 6.87$]
- 2026-12-31 to 2027-12-31 estimated range: [1.78$, 5.62$]
Financial Metrics affecting the ANVS estimates:
- Positive: with PPE of -2.6 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -34.64 <= 0.30
- Positive: Investing cash flow per share per price, % of 0 > -0.65
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: -0.76 < Inventory ratio change, % of 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -12.84 <= 0
Short-term ANVS quotes
Long-term ANVS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $45.04MM | $26.69MM | $29.70MM |
| Operating Income | $-45.04MM | $-26.69MM | $-29.70MM |
| Non-Operating Income | $-11.17MM | $2.10MM | $0.84MM |
| R&D Expense | $38.79MM | $20.00MM | $25.22MM |
| Income(Loss) | $-56.20MM | $-24.59MM | $-28.85MM |
| Net Income(Loss)* | $-56.20MM | $-24.59MM | $-28.85MM |
| Stockholders Equity | $-7.75MM | $9.31MM | $16.85MM |
| Assets | $10.21MM | $13.93MM | $21.08MM |
| Operating Cash Flow | $-39.97MM | $-21.89MM | $-25.62MM |
| Financing Cash Flow | $17.34MM | $26.69MM | $34.60MM |
| Earnings Per Share** | $-6.23 | $-2.02 | $-1.40 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.